Literature DB >> 1712859

Antigenicity of rabies virus glycoprotein.

A Benmansour1, H Leblois, P Coulon, C Tuffereau, Y Gaudin, A Flamand, F Lafay.   

Abstract

Although the number of antigenic sites on the rabies virus glycoprotein that have been described regularly increases with time, no attempt has been made to carefully evaluate the relative importance of each of these sites. Here we provide a more precise description of the antigenicity of the protein in mice of the H-2d haplotype; we developed this description by using 264 newly isolated monoclonal antibodies (MAbs) and a collection of neutralization-resistant (MAR) mutants. Most of the MAbs (97%) recognized antigenic sites previously described as II and III. One minor antigenic site separated from site III by three amino acids, including a proline, was identified (minor site a). Despite their proximity, there is no overlap between site III and minor site a; i.e., site III-specific MAR mutants were neutralized by the six MAbs defining minor site a, and vice versa. One of our MAbs, 1D1, reacted with sodium dodecyl sulfate-treated glycoprotein in Western blots (immunoblots) under reducing conditions and was therefore probably directed against a linear epitope, A MAR mutant selected with this MAb was still neutralized by MAbs of other specificities. This linear epitope was called G1 (G, Gif). As a general rule, we propose to reserve the term "antigenic site" (either major or minor) for regions of the protein which are defined by several MAbs originating from different fusions and to describe regions of the protein which are defined by a single MAb as epitopes. It would be interesting to test whether the same regions of the rabies virus glycoprotein are antigenic in mice of different haplotypes or in other species.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712859      PMCID: PMC248855     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

Review 1.  Epitopes on protein antigens: misconceptions and realities.

Authors:  W G Laver; G M Air; R G Webster; S J Smith-Gill
Journal:  Cell       Date:  1990-05-18       Impact factor: 41.582

2.  Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine.

Authors:  B Dietzschold; M Gore; D Marchadier; H S Niu; H M Bunschoten; L Otvos; W H Wunner; H C Ertl; A D Osterhaus; H Koprowski
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

3.  Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein.

Authors:  I Seif; P Coulon; P E Rollin; A Flamand
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

4.  Characterization of a new temperature-sensitive and avirulent mutant of the rabies virus.

Authors:  C Préhaud; P Coulon; A Diallo; C Martinet-Edelist; A Flamand
Journal:  J Gen Virol       Date:  1989-01       Impact factor: 3.891

5.  Investigation of the antigenic structure of rabies virus glycoprotein by monoclonal antibodies.

Authors:  M Lafon; J Ideler; W H Wunner
Journal:  Dev Biol Stand       Date:  1984

Review 6.  Rabies virus infection: genetic mutations and the impact on viral pathogenicity and immunity.

Authors:  W H Wunner; B Dietzschold
Journal:  Contrib Microbiol Immunol       Date:  1987

7.  Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein.

Authors:  M Lafon; L Edelman; J P Bouvet; M Lafage; E Montchâtre
Journal:  J Gen Virol       Date:  1990-08       Impact factor: 3.891

8.  Molecular basis of rabies virus virulence. I. Selection of avirulent mutants of the CVS strain with anti-G monoclonal antibodies.

Authors:  P Coulon; P Rollin; M Aubert; A Flamand
Journal:  J Gen Virol       Date:  1982-07       Impact factor: 3.891

9.  Biological characterization of human monoclonal antibodies to rabies virus.

Authors:  B Dietzschold; M Gore; P Casali; Y Ueki; C E Rupprecht; A L Notkins; H Koprowski
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

10.  Antigenic variants of CVS rabies virus with altered glycosylation sites.

Authors:  W H Wunner; B Dietzschold; C L Smith; M Lafon; E Golub
Journal:  Virology       Date:  1985-01-15       Impact factor: 3.616

View more
  50 in total

1.  Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders.

Authors:  H Badrane; N Tordo
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor.

Authors:  Venice Du Pont; Christoph Wirblich; Jeong-Joong Yoon; Robert M Cox; Matthias J Schnell; Richard K Plemper
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

3.  Reversible conformational changes and fusion activity of rabies virus glycoprotein.

Authors:  Y Gaudin; C Tuffereau; D Segretain; M Knossow; A Flamand
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

4.  A unique substitution at position 333 on the glycoprotein of rabies virus street strains isolated from non-hematophagous bats in Brazil.

Authors:  G Sato; Y Kobayashi; N Motizuki; S Hirano; T Itou; E M S Cunha; F H Ito; T Sakai
Journal:  Virus Genes       Date:  2008-10-22       Impact factor: 2.332

5.  Folding of rabies virus glycoprotein: epitope acquisition and interaction with endoplasmic reticulum chaperones.

Authors:  Y Gaudin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

6.  An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro.

Authors:  P Coulon; J P Ternaux; A Flamand; C Tuffereau
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  Identification of amino acids controlling the low-pH-induced conformational change of rabies virus glycoprotein.

Authors:  Y Gaudin; H Raux; A Flamand; R W Ruigrok
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

8.  Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants.

Authors:  Alexander B H Bakker; Wilfred E Marissen; R Arjen Kramer; Amy B Rice; William C Weldon; Michael Niezgoda; Cathleen A Hanlon; Sandra Thijsse; Harold H J Backus; John de Kruif; Bernhard Dietzschold; Charles E Rupprecht; Jaap Goudsmit
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

9.  Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity.

Authors:  H Badrane; C Bahloul; P Perrin; N Tordo
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

10.  Cellular uptake mechanism and therapeutic utility of a novel peptide in targeted-delivery of proteins into neuronal cells.

Authors:  Ailing Fu; Zizhen Zhao; Feiyan Gao; Miaomiao Zhang
Journal:  Pharm Res       Date:  2013-05-15       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.